Trial reportVox sanguinis2026
In vitro evaluation of apheresis platelet and plasma products collected and stored in non-DEHP disposable sets.
Trial report in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND AND
objectivesDi(2-ethylhexyl) phthalate (DEHP) has been classified as a reproductive toxicant and endocrine disruptor and will be banned in the European Union (EU) in blood bags starting in July 2030. Alternative plasticizers are being developed, and this study is the first to report on platelets and plasma collected using investigational non-DEHP apheresis sets. MATERIALS AND
methodsRandomized, crossover collections of platelet and plasma products from identical participants in DEHP and non-DEHP sets were performed. Plasma was studied as fresh frozen plasma (FFP) and stored in non-DEHP bags. Additional plasma-only collections evaluated plasma frozen within 24 h after phlebotomy and held at room temperature for up to 24 h (PF24RT24). Platelet and plasma quality parameters were evaluated against the US Food and Drug Administration (FDA) and the European Directorate for the Quality of Medicines & HealthCare (EDQM) criteria.
resultsPlatelet products (n = 33 pairs) met all FDA/EDQM standards, and in vitro parameters were within the predetermined 20% equivalency margin. FFP products (n = 33 pairs) met the EDQM criteria. Factor VIII retention after ≥30 days of frozen storage was on average 88.4%. All parameters for PF24RT24 products (n = 31 pairs) met the 20% equivalency margin after >31 days of frozen storage. No serious adverse events in study participants were reported.
conclusionNon-DEHP apheresis disposable sets collect transfusion-quality platelet and plasma components, supporting the phasing out of DEHP and reducing exposure to this plasticizer, without compromising participant safety and quality of the collected products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.